AstraZeneca-linked studies: OlympiaN, ZEAL and CHIO3 post results; two new studies registeredSep 25Weekly roundup, 7 itemsAstraZenecaAZD0120
AstraZeneca week: Imfinzi label update, ASSURE CLL results posted, four trials registeredSep 3Weekly roundup, 6 itemsacalabrutinibAstraZeneca
Summit's partner Akeso reports positive Phase III data for ivonescimab in bile duct cancerAug 26Clinical readoutivonescimabSummit Therapeutics
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Olaparib Phase 2 results posted; three diabetes labels updated; new myeloma CAR-T trial recruitsAug 14Weekly roundup, 9 itemsAstraZenecaAZD0120
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
AIM ImmunoTech reports Q2 2026 results, cites pancreatic cancer trial progress toward Phase 3Aug 10Quarterly updateAIM ImmunoTech Inc.
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinomaJul 20Clinical readoutMolecular Partners AG
Sign inSign in